Iradimed (IRMD) officer RSU conversion and share disposition details disclosed

Rhea-AI Filing Summary

Iradimed Corporation reported an insider equity transaction by an officer serving as Chief Commercial Officer. On December 11, 2025, the officer converted 996 restricted stock units into common stock and disposed of 309 shares at $97.38 per share, resulting in 687 shares of common stock held directly afterward.

The restricted stock units were granted under Iradimed’s 2023 Equity Incentive Plan and convert into common stock on a one-for-one basis. They vest in three equal annual installments beginning on December 11, 2025. Following this activity, the officer beneficially owned 1,994 restricted stock units in addition to the directly held common stock.

Insider Trade Summary

996 shares exercised/converted

Mixed 3 txns

Insider Chiprin Jeff

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	996	$0.00	--
Exercise	Common Stock	996	$0.00	--
Tax Withholding	Common Stock	309	$97.38	$30K

Holdings After Transaction: Restricted Stock Units — 1,994 shares (Direct); Common Stock — 996 shares (Direct)

Footnotes (1)

1. Restricted stock units convert into common stock on a one-for-one basis. The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chiprin Jeff

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		M		996(1)	A	(1)	996	D
Common Stock	12/11/2025		F		309	D	$97.38	687	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	12/11/2025		M			996	(2)	(2)	Common Stock	996	$0	1,994	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

	/s/ Jeff Chiprin	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Iradimed (IRMD) report in this filing?

An officer of Iradimed Corporation reported converting 996 restricted stock units into common stock and disposing of 309 shares, leaving 687 shares of common stock held directly.

How many restricted stock units did the Iradimed (IRMD) officer convert and at what ratio?

The officer converted 996 restricted stock units, which convert into common stock on a one-for-one basis, resulting in 996 shares of common stock before subsequent dispositions.

At what price were Iradimed (IRMD) shares disposed of in the reported transaction?

The filing shows that 309 shares of common stock were disposed of at a price of $97.38 per share on December 11, 2025.

How many Iradimed (IRMD) shares did the officer own after the transaction?

After the reported transactions, the officer held 687 shares of Iradimed common stock directly.

How many restricted stock units remain outstanding for the Iradimed (IRMD) officer?

Following the transaction, the officer beneficially owned 1,994 restricted stock units, which are tied to Iradimed common stock.

What is the vesting schedule for the Iradimed (IRMD) restricted stock units?

The restricted stock units were granted under Iradimed’s 2023 Equity Incentive Plan and vest in three equal annual installments beginning on December 11, 2025.

What is the reporting person’s role at Iradimed (IRMD)?

The reporting person is identified as an officer of Iradimed Corporation, serving as Chief Commercial Officer.